Abstract: The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

Abstract: The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

Abstract: The invention is directed to a method for detection of single nucleotide polymorphisms utilizing a solid phase RFLP-based method of detection. The invention further relates to a method of detecting a single nucleotide polymorphism (SNP) comprising providing a sample test DNA molecule containing an SNP site of interest; detectably labeling the DNA molecule at or near each of its ends with different labels and containing the SNP site of interest; providing at least two different immobilization oligonucleotides capable of immobilization to a solid support; digesting the test DNA molecule with a restriction endonuclease, whose cut site contains the SNP site in at least one allele of the SNP site; separating strands of the test DNA molecule; annealing the strands to the immobilization oligonucleotides; and detecting the labels of DNA strands annealed to the immobilization oligonucleotide.